Why the study?
Infectious and inflammatory factors may contribute to the incidence of atrial fibrillation, but their causal role remains unclear.
Do genetically predicted higher levels of Epstein-Barr Virus EBNA-1 antibodies reduce the risk of atrial fibrillation in individuals of European descent?
Observational (n=287,805)
Do genetically predicted higher levels of Epstein-Barr Virus EBNA-1 antibodies reduce the risk of atrial fibrillation in individuals of European descent?
Odds Ratio: 0.961 (95% CI 0.933–0.989)
p-value: p=0.006
Genetically predicted higher levels of Epstein-Barr Virus EBNA-1 antibodies may be associated with a reduced risk of atrial fibrillation, highlighting a potential role for infection- and inflammation-related pathways in AF pathogenesis.
Background: Atrial fibrillation (AF) represents the most prevalent form of sustained arrhythmia, with emerging evidence indicating that infectious and inflammatory factors may play a contributory role in its incidence. Methods: Genetic instruments associated with antibody responses to 13 pathogens were obtained from the GWAS Catalog, while summary statistics for atrial fibrillation (AF) were sourced from the Finnish Biobank. A two-sample Mendelian randomization (MR) analysis was conducted, employing inverse variance weighting (IVW) as the primary analytical approach, supplemented by the weighted median estimator (WME) and MR-Egger regression for robustness checks. Results: = 0.006). The weighted median estimator (WME) corroborated these findings, although the MR-Egger regression did not yield significant results. Notable heterogeneity was detected, warranting cautious interpretation of the results. Conclusion: Our findings indicate a possible protective relationship between Epstein-Barr Virus (EBV) EBNA-1 antibody levels and atrial fibrillation (AF). Despite the limitations in establishing causality due to heterogeneity and pleiotropy, this study underscores the significance of infection- and inflammation-related pathways in AF and lays the groundwork for future mechanistic and clinical investigations.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) conducted an observational in Atrial fibrillation (n=287,805). Epstein-Barr Virus (EBV) EBNA-1 antibody levels vs. Lower antibody levels was evaluated on Atrial fibrillation (OR 0.961, 95% CI 0.933-0.989, p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: